Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease November 9, 2015
Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference October 7, 2015
Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule September 28, 2015
Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73 August 12, 2015
